Theralase Technologies Inc. - Asset Resilience Ratio
Theralase Technologies Inc. (TLT) has an Asset Resilience Ratio of 5.90% as of September 2006. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check TLT PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2005)
This chart shows how Theralase Technologies Inc.'s Asset Resilience Ratio has changed over time. See debt-free asset ratio of Theralase Technologies Inc. to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Theralase Technologies Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Theralase Technologies Inc. market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$219.63K | 5.9% |
| Total Liquid Assets | CA$219.63K | 5.90% |
Asset Resilience Insights
- Limited Liquidity: Theralase Technologies Inc. maintains only 5.90% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Theralase Technologies Inc. Industry Peers by Asset Resilience Ratio
Compare Theralase Technologies Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medacta Group SA
SW:MOVE |
Medical Devices | 0.86% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
Xiangyu Medical Co. Ltd. A
SHG:688626 |
Medical Devices | 1.53% |
|
INKON Life Technology Co Ltd
SHE:300143 |
Medical Devices | 5.73% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
Annual Asset Resilience Ratio for Theralase Technologies Inc. (2004–2005)
The table below shows the annual Asset Resilience Ratio data for Theralase Technologies Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2005-12-31 | 8.86% | CA$314.50K ≈ $227.51K |
CA$3.55 Million ≈ $2.57 Million |
-23.98pp |
| 2004-12-31 | 32.84% | CA$399.01K ≈ $288.64K |
CA$1.22 Million ≈ $878.97K |
-- |
About Theralase Technologies Inc.
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form … Read more